{"id":"NCT04707391","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","officialTitle":"A Phase IIIB, Randomized, Controlled, Observer-blind Study to Evaluate Safety and Immunogenicity of GSK's Meningococcal ABCWY Vaccine When Administered in Healthy Adolescents and Adults, Previously Primed With Meningococcal ACWY Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-25","primaryCompletion":"2023-05-03","completion":"2023-09-29","firstPosted":"2021-01-13","resultsPosted":"2024-07-03","lastUpdate":"2024-07-03"},"enrollment":1250,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis, Meningococcal"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"MenABCWY vaccine","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"MenACWY vaccine","otherNames":["Menveo"]},{"type":"COMBINATION_PRODUCT","name":"MenB vaccine","otherNames":["Bexsero"]}],"arms":[{"label":"ABCWY Group","type":"EXPERIMENTAL"},{"label":"ACWY Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.","primaryOutcome":{"measure":"Percentages of Participants With a 4-fold Rise in Human Serum Bactericidal Assay (hSBA) Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the Second MenABCWY Vaccination and the Single MenACWY Vaccination, Relative to Baseline","timeFrame":"At 1 month after vaccination schedule (i.e., Day 211 for ABCWY group and Day 31 for ACWY group) compared to Day 1 (Baseline)","effectByArm":[{"arm":"ABCWY Group","deltaMin":95.3,"sd":null},{"arm":"ACWY Group","deltaMin":95,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":69,"countries":["United States","Argentina","Australia","Canada"]},"refs":{"pmids":["39722560"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":626},"commonTop":["Administration site pain","Headache","Fatigue","Nausea","Myalgia"]}}